- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06322446
Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy (FIQMODE)
Effects of a Strength Exercise Program on Muscular Health in People With CF Treated With Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Receptor (CFTR)
Study Overview
Detailed Description
Specific objectives
- To determine the effects of a strength exercise intervention in a group of children and adolescents with cystic fibrosis treated with new generation CFTR modulators on: (1.i) peripheral muscle strength; (1.ii) respiratory muscle strength; (1.iii) muscle mass and (1.iv) biomarkers of muscle damage.
- To determine the effects of a strength exercise intervention in a group of children and adolescents with cystic fibrosis being treated with new generation CFTR modulators on: (2.i) cardiorespiratory fitness; (2.ii) body composition and (2.iii) lung function.
- To determine the effects of a strength-based exercise intervention in a group of children and adolescents with cystic fibrosis treated with new-generation CFTR modulators on: (3.i) biomarkers of inflammatory status and (3.ii) expression of associated miRNAs.
- To determine the effects of a strength-based exercise intervention in a group of children and adolescents with cystic fibrosis treated with the new generation CFTR modulators on the levels of Elexaxcaftor/Ivacaftor/Tezacaftor and their metabolites.
- To assess the clinical evolution and adherence to exercise after 6 months of the programme in children and adolescents with cystic fibrosis treated with the new generation of CFTR modulators.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Margarita Pérez Ruiz, PhD
- Phone Number: Ext. 77960 +34910677960
- Email: margarita.perez@upm.es
Study Locations
-
-
-
Madrid, Spain, 28040
- Recruiting
- Facultad de Ciencias de la Actividad Física y Deporte - INEF UPM
-
Contact:
- Marcela González Gross, PhD
- Phone Number: +34910677980
- Email: marcela.gonzalez.gross@upm.es
-
Principal Investigator:
- Margarita M Pérez-Ruiz, PhD
-
Sub-Investigator:
- Marcela González-Gross, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients diagnosed with CF.
- patients between 6-20 years of age.
- patients receiving treatment with new CFTR protein modulating medication
- reading, acceptance and signing of the informed consent form.
Exclusion Criteria:
- CF patients with symptoms of pulmonary exacerbation during the last four weeks.
- with a diagnosis of other cardiorespiratory lung diseases progressing to a symptom of persistent respiratory dysfunction.
- CF patients with musculoskeletal alterations that influence assessments.
- CF patient who is pregnant during the time of the study
- CF patient with cognitive impairment;
- CF patient with incomplete dosing of modulator therapy;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Telematic Exercise: A remotely supervised resistance exercise program will be carried out for 16 weeks, with two weekly sessions lasting approximately 60 minutes each. Training will be performed in groups of four patients, according to their lung function/physical fitness. The first training session will be on site (University) for familiarization, planning and adjustment of the exercises, and the following sessions will be performed online. Each session is divided into: (i) Warm-up and joint mobility; (ii) main part: strength exercises for different muscle groups; and (iii) cool down: stretching and breathing exercises. |
16-week exercise intervention: At the beginning of the intervention, we will conduct a face-to-face familiarisation session with the exercises of the training programme.
The intervention will consist of 2 sessions/week for 16 weeks.
Each session consists of three stages: (i) Warm-up: 10 min of joint mobility and low intensity exercises involving the musculature to be worked in that session; (ii) Main part: circuit training mainly composed of strength exercises targeting the different muscle groups of the body and playing activities (iii) Cool down: 10 min with guided breathing work and stretching of the main muscle groups worked
|
No Intervention: Control
Control group will follow routine recommendations from the multidisciplinary CF team based on WHO´s guidelines
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in peripheral muscle strength
Time Frame: Baseline, pre-intervention and immediately after the intervention.
|
Upper and lower limbs muscle strength (kg) will be evaluated using dynamometers.
|
Baseline, pre-intervention and immediately after the intervention.
|
Changes in inspiratory/expiratory muscle strength (MIP/MEP) (cmH2O)
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Inspiratory and expiratory muscle strength: maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be measured.
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in functional capacity: lower limbs power capacity
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
30 seconds sit-to-stand test.
Unit of measurement: number of repetitions.
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in functional capacity: walking capacity
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
10m Time (s) Up and Go tests.
|
Baseline, pre-intervention and immediately after the intervention
|
Change in Cardiorespiratory fitness: maximal oxygen consumption
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
To assess cardiorespiratory fitness, a treadmill and a gas analyser will be used.
The test aims to determine maximal oxygen consumption (VO2peak in ml/kg/min).
VO2peak will be recorded as the highest value obtained during a continuous 30 s period.
|
Baseline, pre-intervention and immediately after the intervention
|
Change in Cardiorespiratory fitness: Ventilatory threshold VT1
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
To assess cardiorespiratory fitness, a treadmill and a gas analyser will be used.
The test aims to determine the ventilatory threshold VT1 in response to maximal effort.
VT1 will be determined using the criteria of an increase in both ventilatory equivalent for oxygen consumption (VE/VO2) and end-tidal oxygen pressure without an increase in ventilatory equivalent for carbon dioxide production (VE/VCO2).
|
Baseline, pre-intervention and immediately after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Pulmonary Function: forced vital capacity (FVC)
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Spirometry will assess: forced vital capacity (FVC) in milliliters and percentage of predicted value
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in Pulmonary Function: Forced expiratory volume in the first second (FEV1)
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Spirometry will assess: forced expiratory volume in the first second (FEV1).Data will be expressed in absolute values and z-score based on the Global Lung Initiative (GLI) reference equation establishing as a limit of normality (LIN) a z-score value for FEV1 between -1.64 and + 1.64.
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in the anthropometric and body composition: Weight
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Weight (kg)
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in the anthropometric and body composition: Height
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Height (cm)
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in the anthropometric and body composition: BMI
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
BMI (kg/m2)
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in body composition: Total fat mass
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Total fat mass (kg)
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in body composition: FMI
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
fat mass index (FMI) (kg/m2),
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in body composition: lean mass kg
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Lean mass in kg
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in body composition: lean mass %
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Lean mass in %
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in quality of life using the Cystic Fibrosis Questionnaire
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Scores range from 0 to 100 with higher scores corresponding to better quality of life.
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in plasma levels muscle damage biomarkers
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Blood levels biomarkers of muscle damage as CK measured in micrograms per litre (mcg/L)
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in plasma levels of inflammation: hs-CRP
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
High-sensitivity C-reactive protein (hs-CRP) assay in milligrams/litre
|
Baseline, pre-intervention and immediately after the intervention
|
Changes in plasma levels of inflammation: Interleukins
Time Frame: Baseline, pre-intervention and immediately after the intervention
|
Analysis of interleukins such as IL6, IL-10 in picograms/millilitre
|
Baseline, pre-intervention and immediately after the intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Margarita Perez Ruiz, PhD, Universidad Politecnica de Madrid
Publications and helpful links
General Publications
- Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81.
- Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, Nieuwenhuis EE, van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013 Jul;19(7):939-45. doi: 10.1038/nm.3201. Epub 2013 Jun 2.
- Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066-73. doi: 10.1126/science.2475911. Erratum In: Science 1989 Sep 29;245(4925):1437.
- Elborn JS. Cystic fibrosis. Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29.
- Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med. 1992 Dec 17;327(25):1785-8. doi: 10.1056/NEJM199212173272504.
- Tejero Garcia S, Giraldez Sanchez MA, Cejudo P, Quintana Gallego E, Dapena J, Garcia Jimenez R, Cano Luis P, Gomez de Terreros I. Bone health, daily physical activity, and exercise tolerance in patients with cystic fibrosis. Chest. 2011 Aug;140(2):475-481. doi: 10.1378/chest.10-1508. Epub 2011 Feb 3.
- van de Weert-van Leeuwen PB, Hulzebos HJ, Werkman MS, Michel S, Vijftigschild LA, van Meegen MA, van der Ent CK, Beekman JM, Arets HG. Chronic inflammation and infection associate with a lower exercise training response in cystic fibrosis adolescents. Respir Med. 2014 Mar;108(3):445-52. doi: 10.1016/j.rmed.2013.08.012. Epub 2013 Aug 28.
- Gao M, Huang Y, Wang Q, Liu K, Sun G. Effects of High-Intensity Interval Training on Pulmonary Function and Exercise Capacity in Individuals with Chronic Obstructive Pulmonary Disease: A Meta-Analysis and Systematic Review. Adv Ther. 2022 Jan;39(1):94-116. doi: 10.1007/s12325-021-01920-6. Epub 2021 Nov 18. Erratum In: Adv Ther. 2022 Jul;39(7):3424.
- Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989 Sep 8;245(4922):1073-80. doi: 10.1126/science.2570460.
- From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO); Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA, Shazam Hussain M, Jansen O, Jayaraman MV, Khalessi AA, Kluck BW, Lavine S, Meyers PM, Ramee S, Rufenacht DA, Schirmer CM, Vorwerk D. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018 Aug;13(6):612-632. doi: 10.1177/1747493018778713. Epub 2018 May 22. No abstract available.
- Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castanos C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27. Erratum In: Lancet Respir Med. 2019 Dec;7(12):e40.
- Rommens JM, Zengerling-Lentes S, Kerem B, Melmer G, Buchwald M, Tsui LC. Physical localization of two DNA markers closely linked to the cystic fibrosis locus by pulsed-field gel electrophoresis. Am J Hum Genet. 1989 Dec;45(6):932-41.
- Bergeron C, Cantin AM. Cystic Fibrosis: Pathophysiology of Lung Disease. Semin Respir Crit Care Med. 2019 Dec;40(6):715-726. doi: 10.1055/s-0039-1694021. Epub 2019 Oct 28.
- Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in Cystic Fibrosis. J Cyst Fibros. 2017 Nov;16 Suppl 2:S70-S78. doi: 10.1016/j.jcf.2017.06.011.
- Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2018 May;34(3):146-151. doi: 10.1097/MOG.0000000000000432.
- Ratchford TL, Teckman JH, Patel DR. Gastrointestinal pathophysiology and nutrition in cystic fibrosis. Expert Rev Gastroenterol Hepatol. 2018 Sep;12(9):853-862. doi: 10.1080/17474124.2018.1502663. Epub 2018 Aug 3.
- Quinton PM. Cystic fibrosis: lessons from the sweat gland. Physiology (Bethesda). 2007 Jun;22:212-25. doi: 10.1152/physiol.00041.2006.
- Shteinberg M, Taylor-Cousar JL, Durieu I, Cohen-Cymberknoh M. Fertility and Pregnancy in Cystic Fibrosis. Chest. 2021 Dec;160(6):2051-2060. doi: 10.1016/j.chest.2021.07.024. Epub 2021 Jul 18.
- Reznikov LR. Cystic Fibrosis and the Nervous System. Chest. 2017 May;151(5):1147-1155. doi: 10.1016/j.chest.2016.11.009. Epub 2016 Nov 19.
- Khalaf M, Scott-Ward T, Causer A, Saynor Z, Shepherd A, Gorecki D, Lewis A, Laight D, Shute J. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Human Lung Microvascular Endothelial Cells Controls Oxidative Stress, Reactive Oxygen-Mediated Cell Signaling and Inflammatory Responses. Front Physiol. 2020 Jul 29;11:879. doi: 10.3389/fphys.2020.00879. eCollection 2020.
- Tousson A, Van Tine BA, Naren AP, Shaw GM, Schwiebert LM. Characterization of CFTR expression and chloride channel activity in human endothelia. Am J Physiol. 1998 Dec;275(6):C1555-64. doi: 10.1152/ajpcell.1998.275.6.C1555.
- Plebani R, Tripaldi R, Lanuti P, Recchiuti A, Patruno S, Di Silvestre S, Simeone P, Anile M, Venuta F, Prioletta M, Mucilli F, Del Porto P, Marchisio M, Pandolfi A, Romano M. Establishment and long-term culture of human cystic fibrosis endothelial cells. Lab Invest. 2017 Nov;97(11):1375-1384. doi: 10.1038/labinvest.2017.74. Epub 2017 Jul 31.
- Totani L, Plebani R, Piccoli A, Di Silvestre S, Lanuti P, Recchiuti A, Cianci E, Dell'Elba G, Sacchetti S, Patruno S, Guarnieri S, Mariggio MA, Mari VC, Anile M, Venuta F, Del Porto P, Moretti P, Prioletta M, Mucilli F, Marchisio M, Pandolfi A, Evangelista V, Romano M. Mechanisms of endothelial cell dysfunction in cystic fibrosis. Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3243-3253. doi: 10.1016/j.bbadis.2017.08.011. Epub 2017 Aug 25.
- Calella P, Valerio G, Brodlie M, Donini LM, Siervo M. Cystic fibrosis, body composition, and health outcomes: a systematic review. Nutrition. 2018 Nov;55-56:131-139. doi: 10.1016/j.nut.2018.03.052. Epub 2018 Apr 6.
- Galluzzi L, Kroemer G. Etiological involvement of CFTR in apparently unrelated human diseases. Mol Cell Oncol. 2018 Dec 27;6(1):1558874. doi: 10.1080/23723556.2018.1558874. eCollection 2019. No abstract available.
- Zemanick ET, Ong T, Daines CL, Dellon EP, Muhlebach MS, Esther CR Jr. Highlights from the 2015 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2016 Jun;51(6):650-7. doi: 10.1002/ppul.23441. Epub 2016 Apr 13.
- Angelis A, Kanavos P, Lopez-Bastida J, Linertova R, Nicod E, Serrano-Aguilar P; BURQOL-RD Research Network. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015 Sep 28;15:428. doi: 10.1186/s12913-015-1061-3.
- Nichols DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Sagel SD, Rosenfeld M, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Kirby S, VanDalfsen JM, Clancy JP, Rowe SM. PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros. 2021 Mar;20(2):205-212. doi: 10.1016/j.jcf.2021.02.003. Epub 2021 Feb 19.
- Burgener EB, Moss RB. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Curr Opin Pediatr. 2018 Jun;30(3):372-377. doi: 10.1097/MOP.0000000000000627.
- Gramegna A, Contarini M, Aliberti S, Casciaro R, Blasi F, Castellani C. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int J Mol Sci. 2020 Aug 16;21(16):5882. doi: 10.3390/ijms21165882.
- Elborn JS. Adult Care in Cystic Fibrosis. Semin Respir Crit Care Med. 2019 Dec;40(6):857-868. doi: 10.1055/s-0039-3400289. Epub 2019 Dec 30.
- Williams CA, Barker AR, Denford S, van Beurden SB, Bianchim MS, Caterini JE, Cox NS, Mackintosh KA, McNarry MA, Rand S, Schneiderman JE, Wells GD, Anderson P, Beever D, Beverley Z, Buckley R, Button B, Causer AJ, Curran M, Dwyer TJ, Gordon W, Gruet M, Harris RA, Hatziagorou E, Erik Hulzebos HJ, Kampouras A, Morrison L, Camara MN, Reilly CM, Sawyer A, Saynor ZL, Shelley J, Spencer G, Stanford GE, Urquhart DS, Young R, Tomlinson OW; Youth Activity Unlimited - A Strategic Research Centre of the UK Cystic Fibrosis Trust. The Exeter Activity Unlimited statement on physical activity and exercise for cystic fibrosis: methodology and results of an international, multidisciplinary, evidence-driven expert consensus. Chron Respir Dis. 2022 Jan-Dec;19:14799731221121670. doi: 10.1177/14799731221121670.
- Hebestreit H, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, Schenk T, Posselt HG, Kriemler S. Long-term effects of a partially supervised conditioning programme in cystic fibrosis. Eur Respir J. 2010 Mar;35(3):578-83. doi: 10.1183/09031936.00062409. Epub 2009 Jul 30.
- Dwyer TJ, Alison JA, McKeough ZJ, Daviskas E, Bye PTP. Effects of exercise on respiratory flow and sputum properties in patients with cystic fibrosis. Chest. 2011 Apr;139(4):870-877. doi: 10.1378/chest.10-1158. Epub 2010 Sep 9.
- Prevotat A, Godin J, Bernard H, Perez T, Le Rouzic O, Wallaert B. Improvement in body composition following a supervised exercise-training program of adult patients with cystic fibrosis. Respir Med Res. 2019 May;75:5-9. doi: 10.1016/j.resmer.2019.04.001. Epub 2019 Apr 13.
- Burtin C, Hebestreit H. Rehabilitation in patients with chronic respiratory disease other than chronic obstructive pulmonary disease: exercise and physical activity interventions in cystic fibrosis and non-cystic fibrosis bronchiectasis. Respiration. 2015;89(3):181-9. doi: 10.1159/000375170. Epub 2015 Feb 12.
- Saynor ZL, Gruet M, Rodriguez-Miguelez P, Harris RA. Oxygen transport and utilisation during exercise in cystic fibrosis: contributors to exercise intolerance. Exp Physiol. 2020 Dec;105(12):1979-1983. doi: 10.1113/EP088106. Epub 2020 Nov 11.
- Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros. 2015 Jul;14(4):419-30. doi: 10.1016/j.jcf.2015.03.003. Epub 2015 Mar 23.
- Gruber W, Orenstein DM, Braumann KM, Beneke R. Interval exercise training in cystic fibrosis -- effects on exercise capacity in severely affected adults. J Cyst Fibros. 2014 Jan;13(1):86-91. doi: 10.1016/j.jcf.2013.06.005. Epub 2013 Jul 15.
- Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015 Jul;16(7):421-33. doi: 10.1038/nrg3965. Epub 2015 Jun 16.
- Ideozu JE, Zhang X, Rangaraj V, McColley S, Levy H. Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis. Sci Rep. 2019 Oct 29;9(1):15483. doi: 10.1038/s41598-019-51890-7.
- Catellani C, Cirillo F, Graziano S, Montanini L, Marmiroli N, Gulli M, Street ME. MicroRNA global profiling in cystic fibrosis cell lines reveals dysregulated pathways related with inflammation, cancer, growth, glucose and lipid metabolism, and fertility: an exploratory study. Acta Biomed. 2022 Jul 1;93(3):e2022133. doi: 10.23750/abm.v93i3.12842.
- Bene Z, Fejes Z, Szanto TG, Fenyvesi F, Varadi J, Clarke LA, Panyi G, Macek M Jr, Amaral MD, Balogh I, Nagy B Jr. Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells. Front Pharmacol. 2021 May 14;12:592184. doi: 10.3389/fphar.2021.592184. eCollection 2021.
- Fontes G, Ghislain J, Benterki I, Zarrouki B, Trudel D, Berthiaume Y, Poitout V. The DeltaF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Is Associated With Progressive Insulin Resistance and Decreased Functional beta-Cell Mass in Mice. Diabetes. 2015 Dec;64(12):4112-22. doi: 10.2337/db14-0810. Epub 2015 Aug 17.
- Plebani R, Potla R, Soong M, Bai H, Izadifar Z, Jiang A, Travis RN, Belgur C, Dinis A, Cartwright MJ, Prantil-Baun R, Jolly P, Gilpin SE, Romano M, Ingber DE. Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip. J Cyst Fibros. 2022 Jul;21(4):606-615. doi: 10.1016/j.jcf.2021.10.004. Epub 2021 Nov 17.
- Fiz JA, Montserrat JM, Picado C, Plaza V, Agusti-Vidal A. How many manoeuvres should be done to measure maximal inspiratory mouth pressure in patients with chronic airflow obstruction? Thorax. 1989 May;44(5):419-21. doi: 10.1136/thx.44.5.419.
- Murillo AMM, Tome-Amat J, Ramirez Y, Garrido-Arandia M, Valle LG, Hernandez-Ramirez G, Tramarin L, Herreros P, Santamaria B, Diaz-Perales A, Holgado M. Developing an Optical Interferometric Detection Method based biosensor for detecting specific SARS-CoV-2 immunoglobulins in Serum and Saliva, and their corresponding ELISA correlation. Sens Actuators B Chem. 2021 Oct 15;345:130394. doi: 10.1016/j.snb.2021.130394. Epub 2021 Jul 3.
- Donadio MVF, Cobo-Vicente F, San Juan AF, Sanz-Santiago V, Fernandez-Luna A, Iturriaga T, Villa Asensi JR, Perez-Ruiz M. Is exercise and electrostimulation effective in improving muscle strength and cardiorespiratory fitness in children with cystic fibrosis and mild-to-moderate pulmonary impairment?: Randomized controlled trial. Respir Med. 2022 May;196:106798. doi: 10.1016/j.rmed.2022.106798. Epub 2022 Mar 1.
- Divangahi M, Balghi H, Danialou G, Comtois AS, Demoule A, Ernest S, Haston C, Robert R, Hanrahan JW, Radzioch D, Petrof BJ. Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet. 2009 Jul;5(7):e1000586. doi: 10.1371/journal.pgen.1000586. Epub 2009 Jul 31.
- King JA, Nichols AL, Bentley S, Carr SB, Davies JC. An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Paediatr Drugs. 2022 Jul;24(4):321-333. doi: 10.1007/s40272-022-00509-y. Epub 2022 May 16.
- Rodriguez-Miguelez P, Seigler N, Ishii H, Crandall R, McKie KT, Forseen C, Harris RA. Exercise Intolerance in Cystic Fibrosis: Importance of Skeletal Muscle. Med Sci Sports Exerc. 2021 Apr 1;53(4):684-693. doi: 10.1249/MSS.0000000000002521.
- Wells GD, Wilkes DL, Schneiderman JE, Rayner T, Elmi M, Selvadurai H, Dell SD, Noseworthy MD, Ratjen F, Tein I, Coates AL. Skeletal muscle metabolism in cystic fibrosis and primary ciliary dyskinesia. Pediatr Res. 2011 Jan;69(1):40-5. doi: 10.1203/PDR.0b013e3181fff35f.
- Bene Z, Fejes Z, Macek M Jr, Amaral MD, Balogh I, Nagy B Jr. Laboratory biomarkers for lung disease severity and progression in cystic fibrosis. Clin Chim Acta. 2020 Sep;508:277-286. doi: 10.1016/j.cca.2020.05.015. Epub 2020 May 16.
- Stachowiak Z, Wojsyk-Banaszak I, Jonczyk-Potoczna K, Narozna B, Langwinski W, Szczepankiewicz A. Extracellular vesicles-derived miRNAs as mediators of pulmonary exacerbation in pediatric cystic fibrosis. J Breath Res. 2023 Feb 10;17(2). doi: 10.1088/1752-7163/acb792.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI23/00299
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Exercise
-
University of Kansas Medical CenterRecruiting
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of
-
University of AlbertaWomen and Children's Health Research Institute, CanadaRecruitingType 1 Diabetes | Post-menopauseCanada
-
Uskudar UniversityCompleted
-
Yuksek Ihtisas UniversityCompletedDementia | Frailty | Cognitive Function | Reaction Time | Aerobic Exercise | Balance ExerciseTurkey
-
National Taiwan Normal UniversityCompletedAging | Cognitive DeclineTaiwan
-
Wayne State UniversityUnknown